Geron Corporation (NASDAQ:GERN) is being accused of knowingly or unknowingly misleading its investors according to a filing by one of the company’s investors. The allegations claim the company and a number of its officers, as well as directors, could have violated the Securities and Exchange Act of 1934 with questionable remarks concerning the drug imetelstat. The misdealing’s according to the filling took place between June 16, 2013 and March 11, 2014. Geron Corporation (NASDAQ:GERN) shares after opening at $2.03 moved to $2.03 on last trade day and at the end of the day closed at $1.90. Company price to sales ratio in past twelve months was calculated as 229.33 and price to cash ratio as 4.57. Geron Corporation (NASDAQ:GERN) showed a negative weekly performance of -2.06%.
On 14 April 2014 Novavax, Inc. (NASDAQ:NVAX)’s contract with BARDA gives it stable revenue stream for the development of next-gen vaccine for influenza. The company received $52 million in the first three-year contract arrangement. The contract was extended for another seven months last February. The money helped Novavax to improve its infrastructure without impacting shareholder value through stock dilution. Novavax, Inc. (NASDAQ:NVAX) shares fell -5.81% in last trading session and ended the day on $3.89. NVAX return on equity ratio is recorded as -41.40% and its return on assets is -34.10%. Novavax, Inc. (NASDAQ:NVAX) yearly performance is 55.60%.
Illumina (NASDAQ:ILMN) announced that the company has filed a new patent infringement suit against Ariosa Diagnostics, Inc.Illumina is seeking all available remedies, including injunctive relief. Illumina, Inc. (NASDAQ:ILMN) shares moved down -7.89% in last trading session and was closed at $139.71, while trading in range of $139.51-$150.64. Illumina, Inc. (NASDAQ:ILMN) year to date performance is 26.33%.
Organovo Holdings Inc (NYSEMKT:ONVO) weekly performance is -20.71%. On last trading day company shares ended up $5.55. Organovo Holdings Inc (NYSEMKT:ONVO) distance from 50-day simple moving average is -35.61%.Organovo Holdings, Inc. (NYSEMKT: ONVO) the San Diego-based regenerative medicine company focused on using its breakthrough NovoGen 3D human tissue printing technology to create tissue on demand for medical research and therapeutic applications.